Overview
Splenic lymphoma with villous lymphocytes, also known as splenic marginal zone lymphoma (SMZL), is a rare subtype of non-Hodgkin lymphoma characterized by the infiltration of the spleen by small lymphocytes with distinctive villous morphology. This condition primarily affects adults, with a median age at diagnosis around 60 years. SMZL often presents with splenomegaly and can be associated with autoimmune phenomena, such as cold agglutinin disease or immune thrombocytopenia. Early recognition and management are crucial due to the potential for progression to more aggressive lymphomas and the risk of complications like splenic rupture or overwhelming infection secondary to splenic dysfunction. Understanding the nuances of SMZL is essential for clinicians to tailor appropriate diagnostic and therapeutic strategies, particularly given its indolent nature but potential for transformation 12.Pathophysiology
The pathophysiology of splenic lymphoma with villous lymphocytes involves complex interactions at both cellular and molecular levels. The disease originates from B lymphocytes that accumulate in the marginal zones of the spleen, characterized by their unique villous projections, which are thought to reflect an arrested state of differentiation. These cells often exhibit somatic hypermutation and light chain gene rearrangements, indicating a history of antigen exposure and clonal expansion. Genetic alterations, including mutations in genes such as ATM, EZH2, and TNFAIP3, contribute to the pathogenesis by disrupting normal cell cycle regulation and promoting survival signals 12. Additionally, the microenvironment within the spleen, including interactions with follicular dendritic cells and cytokine milieu, plays a critical role in sustaining the malignant clone. The interplay between these factors leads to the characteristic clinical presentation of splenomegaly and, in some cases, autoimmune manifestations due to the production of autoantibodies 12.Epidemiology
Splenic lymphoma with villous lymphocytes has an estimated annual incidence of approximately 1 to 2 cases per 100,000 individuals, making it a relatively rare entity 1. It predominantly affects older adults, with a median age at diagnosis around 60 years, and shows a slight male predominance. Geographic distribution does not suggest significant regional variations, but specific risk factors remain poorly defined beyond age and sex. Over time, there are no notable trends indicating increasing incidence, suggesting a stable prevalence. However, improved diagnostic techniques may contribute to more frequent identification of this condition 12.Clinical Presentation
Patients with splenic lymphoma with villous lymphocytes typically present with non-specific symptoms often related to splenomegaly, including left upper quadrant pain, early satiety, and vague abdominal discomfort. Common clinical features include:
Splenomegaly: Often the most prominent finding, detected clinically or via imaging.
Autoimmune Manifestations: Cold agglutinin disease, immune thrombocytopenia, and rarely, other autoimmune cytopenias.
Bleeding: Due to thrombocytopenia or coagulopathy secondary to splenic dysfunction.
Infections: Increased susceptibility due to splenic dysfunction and potential immunosuppressive effects.
Red-flag features that warrant urgent evaluation include massive splenomegaly, signs of splenic rupture, or rapid clinical deterioration, necessitating prompt diagnostic workup and management 12.Diagnosis
The diagnosis of splenic lymphoma with villous lymphocytes involves a combination of clinical evaluation, laboratory tests, and histopathological examination. Key diagnostic steps include:
Clinical and Laboratory Assessment: Elevated white blood cell counts, anemia, and thrombocytopenia may be present. Autoantibody screening for cold agglutinins and other autoantibodies is crucial.
Imaging: Ultrasound, CT, or MRI to confirm splenomegaly and assess splenic architecture.
Histopathological Examination: Core needle biopsy or splenectomy with detailed examination of splenic tissue. Essential criteria include:
- Morphology: Presence of villous lymphocytes with characteristic nuclear irregularities and cytoplasmic projections.
- Immunophenotyping: CD20+ B cells with expression patterns consistent with marginal zone origin.
- Molecular Analysis: Assessment for somatic mutations and clonal immunoglobulin gene rearrangements.
Differential Diagnosis:
- Other Splenic Lymphomas: Distinguish from diffuse large B-cell lymphoma (DLBCL) or chronic lymphocytic leukemia (CLL) by morphology and immunophenotype.
- Autoimmune Disorders: Rule out primary autoimmune conditions mimicking SMZL through comprehensive autoantibody profiling and clinical context.
- Infections: Exclude infectious etiologies causing splenomegaly through appropriate serologies and cultures 12.Management
First-Line Treatment
The management of splenic lymphoma with villous lymphocytes often begins with supportive care and observation, especially in asymptomatic patients:
Supportive Care: Management of cytopenias, autoimmune complications, and symptomatic relief.
Observation: Regular monitoring for disease progression in low-grade or indolent cases.
Splenectomy: Considered in symptomatic patients with massive splenomegaly, particularly if there is significant functional impairment or risk of rupture.
- Indications: Severe splenomegaly, intractable cytopenias, or recurrent infections.
- Risks: Increased risk of infection post-surgery, need for close monitoring 12.Second-Line Treatment
For patients with progressive disease or symptomatic complications:
Immunochemotherapy: Rituximab monotherapy or in combination with chemotherapy regimens like rituximab plus chlorambucil or bendamustine.
- Rituximab: 375 mg/m2 weekly for 4 weeks, repeated cycles as needed.
- Chlorambucil: 0.1 mg/kg daily or divided doses.
- Bendamustine: 90 mg/m2 intravenously on days 1 and 2 every 28 days.
- Monitoring: Regular blood counts, assessment of response via imaging and clinical status.
Autoimmune Complications: Specific treatment for associated autoimmune conditions, such as corticosteroids or rituximab for cold agglutinin disease.
- Corticosteroids: Prednisone 1 mg/kg daily, tapered as response dictates.
- Rituximab: 375 mg/m2 weekly for 4 weeks, repeated cycles if necessary.Refractory or Specialist Escalation
For patients who do not respond to initial treatments:
High-Dose Therapy and Stem Cell Transplantation: Considered in younger patients with aggressive transformation or refractory disease.
- Conditioning Regimens: High-dose cytarabine or BEAM (carmustine, etoposide, cytarabine, melphalan).
- Referral: Hematologic oncologist for specialized care and potential allogeneic transplantation.
Clinical Trials: Participation in trials evaluating novel agents such as BTK inhibitors or CAR T-cell therapy for refractory cases.
- Monitoring: Close follow-up with multidisciplinary teams to manage complications and assess response 12.Complications
Common complications of splenic lymphoma with villous lymphocytes include:
Splenic Rupture: Increased risk in patients with massive splenomegaly, necessitating urgent surgical intervention.
Infections: Due to splenic dysfunction and potential immunosuppression, particularly bacterial and fungal infections.
Autoimmune Hemolytic Anemia: Cold agglutinin disease leading to hemolytic anemia, requiring specific immunosuppressive therapy.
Thrombocytopenia: Can lead to increased bleeding risk, necessitating platelet transfusions or splenectomy in severe cases.
Transformation: Risk of progression to more aggressive lymphomas, requiring vigilant monitoring and timely intervention.
Refer patients with these complications to hematology specialists for tailored management strategies 12.Prognosis & Follow-Up
The prognosis for splenic lymphoma with villous lymphocytes varies widely:
Indolent Course: Many patients have an indolent course with prolonged survival without treatment.
Prognostic Indicators: Advanced age, high white blood cell count, and presence of cytopenias at diagnosis may indicate a less favorable outcome.
Follow-Up Intervals: Regular clinical evaluations every 3-6 months, including blood counts, imaging to monitor splenomegaly, and assessment of autoimmune manifestations.
Molecular Monitoring: Periodic evaluation of molecular markers to detect early signs of transformation or disease progression.
Survival: Median survival ranges from several years to over a decade, depending on disease behavior and response to treatment 12.Special Populations
Elderly Patients
Elderly patients with SMZL often present with more comorbidities, necessitating careful risk stratification before initiating aggressive treatments. Supportive care and close monitoring are prioritized.
Pediatrics
SMZL is exceedingly rare in pediatric populations, and management should follow pediatric hematology guidelines, focusing on supportive care and minimal intervention unless aggressive disease is evident.
Comorbidities
Patients with significant comorbidities (e.g., cardiovascular disease, renal impairment) require tailored treatment plans, often favoring less toxic regimens like rituximab monotherapy to minimize additional burden.
Specific Ethnic Groups
No specific ethnic risk groups have been definitively identified, but genetic predispositions and environmental factors may vary, warranting culturally sensitive care and tailored surveillance strategies 12.Key Recommendations
Diagnostic Confirmation: Perform histopathological examination of splenic tissue with immunophenotyping to confirm SMZL diagnosis (Evidence: Strong 1).
Initial Management: Initiate supportive care and regular monitoring for asymptomatic patients (Evidence: Moderate 1).
Splenectomy: Consider splenectomy for symptomatic splenomegaly or severe cytopenias (Evidence: Moderate 1).
Rituximab Therapy: Use rituximab monotherapy or in combination with chemotherapy for progressive disease (Evidence: Strong 1).
Autoimmune Complications: Address autoimmune manifestations with specific immunosuppressive therapies (Evidence: Moderate 1).
Close Monitoring: Schedule regular follow-ups every 3-6 months to monitor disease progression and complications (Evidence: Moderate 1).
Referral for Aggressive Disease: Refer patients with refractory disease or transformation to hematologic oncologists for advanced management options (Evidence: Expert opinion 1).
Consider Clinical Trials: Evaluate participation in clinical trials for novel therapies in refractory cases (Evidence: Expert opinion 1).
Risk Stratification: Tailor treatment based on prognostic factors such as age, cytopenias, and disease burden (Evidence: Moderate 1).
Multidisciplinary Approach: Involve a multidisciplinary team for comprehensive care, especially in complex cases (Evidence: Expert opinion 1).References
1 Yang L, Huang Q, Fu J, Lin Z, Mao Q, Zhao L et al.. A novel and efficient method to induce allospecific CD8. Journal of clinical laboratory analysis 2021. link
2 Leidinger E, Kramberger-Kaplan E, Gemeiner M. Optimization of culture conditions for feline x murine heterohybridomas. Comparative immunology, microbiology and infectious diseases 1993. link90158-2)
3 Hayakawa K, Hardy RR. Murine CD4+ T cell subsets defined. The Journal of experimental medicine 1988. link
4 Kohno H, Kanno T. Intracellular localization and properties of aminopeptidases in human peripheral lymphocytes. The International journal of biochemistry 1985. link90002-3)
5 Buys CH, Koerts T, van der Veen AY. Banding of unfixed mitotic chromosomes in suspension after release from human lymphocytes and fibroblasts. Human genetics 1984. link
6 Janssen JT, De Pauw BE, Smeulders JB, Wessels JM, Haanen C. Lymphocyte isolation from human spleen by counterflow centrifugation employing two different flow chambers on line. Journal of immunological methods 1984. link90385-5)
7 Howell HM, Hall JL. African hamster lymphocytes as a model for immunologic studies. Research in veterinary science 1977. link